8-hydroxy-2-(di-n-propylamino)tetralin has been researched along with Parkinsonian Disorders in 15 studies
8-Hydroxy-2-(di-n-propylamino)tetralin: A serotonin 1A-receptor agonist that is used experimentally to test the effects of serotonin.
8-OH-DPAT : A tetralin substituted at positions 1 and 7 by hydroxy and dipropylamino groups respectively
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "or s." | 5.72 | The selective 5-HT 1A receptor agonist, NLX-112, overcomes tetrabenazine-induced catalepsy and depression-like behavior in the rat. ( Depoortere, R; Jastrzębska-Więsek, M; Kołaczkowski, M; Newman-Tancredi, A; Varney, MA; Wesołowska, A, 2022) |
| "or s." | 1.72 | The selective 5-HT 1A receptor agonist, NLX-112, overcomes tetrabenazine-induced catalepsy and depression-like behavior in the rat. ( Depoortere, R; Jastrzębska-Więsek, M; Kołaczkowski, M; Newman-Tancredi, A; Varney, MA; Wesołowska, A, 2022) |
| "Depression is a common symptom in Parkinson's disease (PD), but its pathophysiology remains unclear." | 1.40 | Activation of prelimbic 5-HT1A receptors produces antidepressant-like effects in a unilateral rat model of Parkinson's disease. ( Chen, L; Guo, Y; Hui, YP; Liu, J; Qiao, HF; Wang, Y; Zhang, L; Zhang, QJ, 2014) |
| " Furthermore, chronic administration of low doses of the 5-HT(1) agonists in combination was able to prevent development of dyskinesia, and reduce the up-regulation of FosB after daily treatment with l-DOPA in the rat 6-OHDA model." | 1.35 | Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. ( Bezard, E; Björklund, A; Carlsson, T; Carta, M; Di Luca, M; Gardoni, F; Kirik, D; Li, Q; Marcello, E; Muñoz, A; Qin, C, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 10 (66.67) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, X | 1 |
| Liang, P | 1 |
| Wang, K | 1 |
| Jia, J | 1 |
| Wang, X | 1 |
| Jastrzębska-Więsek, M | 1 |
| Wesołowska, A | 1 |
| Kołaczkowski, M | 1 |
| Varney, MA | 1 |
| Newman-Tancredi, A | 1 |
| Depoortere, R | 1 |
| Liu, Y | 1 |
| Liu, J | 6 |
| Jiao, SR | 1 |
| Liu, X | 1 |
| Guo, Y | 2 |
| Zhang, J | 1 |
| Yang, J | 1 |
| Xie, W | 1 |
| Wang, HS | 1 |
| Zhang, L | 5 |
| Dupre, KB | 4 |
| Ostock, CY | 1 |
| George, JA | 1 |
| Eskow Jaunarajs, KL | 1 |
| Hueston, CM | 1 |
| Bishop, C | 3 |
| Iderberg, H | 1 |
| Rylander, D | 1 |
| Bimpisidis, Z | 1 |
| Cenci, MA | 1 |
| Li, LB | 2 |
| Han, LN | 2 |
| Zhang, QJ | 3 |
| Sun, YN | 2 |
| Wang, Y | 4 |
| Feng, J | 2 |
| Wang, T | 3 |
| Chen, L | 3 |
| Zhang, Q | 1 |
| Wang, S | 1 |
| Zhang, H | 2 |
| Qiao, H | 1 |
| Niu, X | 1 |
| Hui, YP | 1 |
| Qiao, HF | 1 |
| Zhang, YM | 1 |
| Cruz, AV | 1 |
| McCoy, AJ | 1 |
| Delaville, C | 1 |
| Gerber, CM | 1 |
| Eyring, KW | 1 |
| Walters, JR | 1 |
| Eskow, KL | 2 |
| Steiniger, A | 1 |
| Klioueva, A | 1 |
| Negron, GE | 1 |
| Lormand, L | 1 |
| Park, JY | 1 |
| Mo, J | 1 |
| Yu, LP | 1 |
| Sun, PH | 1 |
| Jin, GZ | 1 |
| Zhen, X | 1 |
| Muñoz, A | 1 |
| Li, Q | 1 |
| Gardoni, F | 1 |
| Marcello, E | 1 |
| Qin, C | 1 |
| Carlsson, T | 1 |
| Kirik, D | 1 |
| Di Luca, M | 1 |
| Björklund, A | 1 |
| Bezard, E | 1 |
| Carta, M | 1 |
| Krolewski, DM | 1 |
| Barnum, CJ | 1 |
| Deak, T | 1 |
| Walker, PD | 1 |
| Hou, C | 1 |
| Xue, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Role of Sleep Homeostasis in the Development of the L-Dopa Induced Dyskinesias in Patients With Parkinson's Disease[NCT02200887] | 48 participants (Actual) | Observational | 2013-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
15 other studies available for 8-hydroxy-2-(di-n-propylamino)tetralin and Parkinsonian Disorders
| Article | Year |
|---|---|
Serotonin 1A receptor agonist modulation of motor deficits and cortical oscillations by NMDA receptor interaction in parkinsonian rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Beta Rhythm; Locomotion; Male; Motor Cortex; Motor | 2022 |
The selective 5-HT 1A receptor agonist, NLX-112, overcomes tetrabenazine-induced catalepsy and depression-like behavior in the rat.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antidepressive Agents; Buspirone; Catalepsy; Depres | 2022 |
Serotonin
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Disease Models, Animal; Dopamine; Habituation, Psyc | 2019 |
Effects of 5-HT1A receptor stimulation on D1 receptor agonist-induced striatonigral activity and dyskinesia in hemiparkinsonian rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Behavior, Animal; Benzazepines; Dopamine Agonists; | 2013 |
Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; 8-Hydroxy-2-(di-n-propylamino)tetralin; | 2013 |
The theta-related firing activity of parvalbumin-positive neurons in the medial septum-diagonal band of Broca complex and their response to 5-HT1A receptor stimulation in a rat model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Action Potentials; Animals; Apomorphine; Desipramine; Diagon | 2014 |
Decreased response of interneurons in the medial prefrontal cortex to 5-HT₁A receptor activation in the rat 6-hydroxydopamine Parkinson model.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Action Potentials; Animals; Dose-Response Relationship, Drug | 2014 |
Activation of prelimbic 5-HT1A receptors produces antidepressant-like effects in a unilateral rat model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antidepressive Agents; Depression; Dietary Sucrose; | 2014 |
Activation of 5-HT₁A receptors in the medial subdivision of the central nucleus of the amygdala produces anxiolytic effects in a rat model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Action Potentials; Animals; Anti-Anxiety Agents; Anxiety Dis | 2015 |
Effects of L-dopa priming on cortical high beta and high gamma oscillatory activity in a rodent model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Benzazepines; Disease Models, Animal; Dopamine Agon | 2016 |
Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Corpus Striatum; Di | 2008 |
L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Antiparkinson Agents; Antipsy | 2010 |
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antip | 2008 |
Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Corpus Striatum; Dynorphins; | 2009 |
Unilateral lesion of the nigrostriatal pathway decreases the response of GABA interneurons in the dorsal raphe nucleus to 5-HT(1A) receptor stimulation in the rat.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Action Potentials; Animals; Cell Count; Corpus Striatum; Dop | 2012 |